Mechanistic and functional differentiation of tapentadol and tramadol

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 10, 2012, Pages 1437-1449

  Raffa, Robert B ^a   Buschmann, Helmut ^b   Christoph, Thomas ^c   Eichenbaum, Gary ^d   Englberger, Werner ^c   Flores, Christopher M ^d   Hertrampf, Torsten ^c   Kögel, Babette ^c   Schiene, Klaus ^c   Straßburger, Wolfgang ^e   Terlinden, Rolf ^c   Tzschentke, Thomas M ^c  

^a TEMPLE UNIVERSITY   (United States)

^b Pharma Consulting Aachen   (Germany)

^c GRÜNENTHAL GMBH   (Germany)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^e NONE

Author keywords

Analgesia; Efficacy; MOR NRI; Synergy; Tapentadol; Tramadol; Translational drug design

Indexed keywords

DRUG METABOLITE; HYDROXYL GROUP; METHYL GROUP; MU OPIATE RECEPTOR; NORADRENALIN; OPIATE RECEPTOR; SEROTONIN; TAPENTADOL; TRAMADOL;

ANALGESIA; AREA UNDER THE CURVE; BINDING AFFINITY; DIMETHYLAMINOMETHYL; DRUG ABUSE; DRUG ACTIVITY; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; ENANTIOMER; HIPPOCAMPUS; HUMAN; MAXIMUM PLASMA CONCENTRATION; MICRODIALYSIS; NONHUMAN; PAIN ASSESSMENT; RACEMIC MIXTURE; REVIEW; STEREOCHEMISTRY;

ANALGESICS, OPIOID; ANIMALS; HUMANS; PAIN; PHENOLS; RECEPTORS, OPIOID, MU; TRAMADOL;

EID: 84863097731     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.696097     Document Type: Review

References (69)

1. Nicholls A, McGaughey GB, Sheridan RP, et al. Molecular shape and medicinal chemistry: A perspective. J Med Chem 2010;53:3862-86
2. Levi P. Other people's trades. Summit Books; New York, NY: 1989
3. Bemis GW, Murcko MA. the properties of known drugs. 1. Molecular frameworks. J Med Chem 1996;39:2887-93
4. Hu Y, Bajorath J. Polypharmacology directed compound data mining: Identification of promiscuous chemotypes with different activity profiles and comparison to approved drugs. J Chem Inf Model 2010;50:2112-18
5. Anderson E, Veith GD, Weininger D. SMILES: A line notation and computerized interpreter for chemical structures. Report No. EPA/600/M-87/021; U.S EPA, Environmental Research Laboratory-Duluth; Duluth, MN: 1987
6. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3-26
7. Hahn M. Three-dimensional shape-based searching of conformationally flexible compounds. J Chem Inf Comput Sci 1997;37:80-6
8. Raffa RB, Tallarida RJ. Affinity: historical development in chemistry and pharmacology. Bull Hist Chem 2010;35:7-16
9. Tao Q, Stone DJ, Borenstein MR, et al. Differential tramadol and O-desmethyl metabolite levels in brain vs. plasma of mice and rats administered tramadol hydrochloride orally. J Clin Pharm Ther 2002;27:99-106
10. Casy AF, Parfitt RT. Opioid analgesics -chemistry and receptors. Plenum Press; New York, NY: 1986
11. Maul C, Buschmann H, Sundermann B. Synthetic opioids. In: Buschmann H, Christoph T, Friderichs E, et al. editors. Analgesics. Wiley-VCH; Weinheim, Germany: 2002. p. 159-69
12. Friderichs E, Buschmann H. Opioids with clinical relevance. In: Buschmann H, Christoph T, Friderichs E, et al. editors. Analgesics -from chemistry and pharmacology to clinical application. Wiley-VCH; Weinheim, Germany: 2002. p. 171-245
13. Hu Y, Stumpfe D, Bajorath J. Lessons learned from molecular scaffold analysis. J Chem Inf Model 2011;51:1742-53
14. Ferenczy GG, Keseru GM. Thermodynamics guided lead discovery and optimization. Drug Discov Today 2010;15:919-32
15. Reynolds CH, Holloway CK. Thermodynamics of ligand binding and efficiency. ACS Med Chem Lett 2011;2:433-7
16. Gleeson MP, Hersey A, Montanari D, Overington J. Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat Rev Drug Discov 2011;10:197-208
17. Bohm H-J, Gerard Klebe G, Kubinyi H. Wirkstoffdesign -Der Weg zum Arzneimittel. Spektrum Akademischer Verlag; Heidelberg, Germany: 1996
18. Agranat I, Caner H, Caldwell J. Putting chirality to work: The strategy of chiral switches. Nat Rev Drug Discov 2002;1:753-68
19. Federsel H-J. Putting chirality to work: The strategy of chiral switches. Chirality 2003;15:128-42
20. Wermuth CG. the Practice of Medicinal Chemistry. Academic Press; Burlington, MA: 2008
21. Milletti F, Vulpetti A. Predicting polypharmacology by binding site similarity: From kinases to the protein universe. J Chem Inf Model 2010;50:1418-31
22. Bottegoni G, Favia AD, Recanatini M, Cavalli A. the role of fragment-based and computational methods in polypharmacology. Drug Discov Today 2012;17:23-34
23. Turk DC, Wilson HD, Cahana A. Treatment of chronic non-cancer pain. Lancet 2011;377:2226-35
24. Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 2005;48:6523-43
25. Zimmermann GR, Lehar J, Keith CT. Multi-target therapeutics: When the whole is greater than the sum of the parts. Drug Discov Today 2007;12:34-42
26. Tzschentke TM, Christoph T, Kogel B, et al. (-)-(1R,2R)-3-(3- Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): -rfaut novel -opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 2007;323:265-76
27. Lai J, Ma SW, Porreca F, Raffa RB. Tramadol, M1 metabolite and enantiomer affinities for cloned human opioid receptors expressed in transfected HN9.10 neuroblastoma cells. Eur J Pharmacol 1996;316:369-72
28. Gillen C, Haurand M, Kobelt DJ, Wnendt S. Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedebergs Arch Pharmacol 2000;362:116-21
29. Bloms-Funke P, Dremencov E, Cremers TI, Tzschentke TM. Tramadol increases extracellular levels of serotonin and noradrenaline as measured by in vivo microdialysis in the ventral hippocampus of freely-moving rats. Neurosci Lett 2011;490:191-5
30. Ceccato A, Vanderbist F, Pabst JY, Streel B. Enantiomeric determination of tramadol and its main metabolite O-desmethyltramadol in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 2000;748:65-76
31. Schroder W, Vry JD, Tzschentke TM, et al. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur J Pain 2010;14:814-21
32. Schiene K, De VJ, Tzschentke TM. Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain. J Pharmacol Exp Ther 2011;339:537-44
33. Raffa RB, Friderichs E, Reimann W, et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther 1992;260:275-85
34. Schroder W, Tzschentke TM, Terlinden R, et al. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia. J Pharmacol Exp Ther 2011;337:312-20
35. Raffa RB, Nayak RK, Liao S, Minn FL. the mechanism(s) of action and pharmacokinetics of tramadol hydrochloride. Rev Contemp Pharmacother 1995;6:485-97
36. Garcia-Quetglas E, Azanza JR, Sadaba B, et al. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype. Pharmacol Res 2007;55:122-30
37. Klotz U. Tramadol-the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. Arzneimittelforschung 2003;53:681-7
38. Terlinden R, Kogel BY, Englberger W, Tzschentke TM. in vitro and in vivo characterization of tapentadol metabolites. Methods Find Exp Clin Pharmacol 2010;32:31-8
39. Kneip C, Terlinden R, Beier H, Chen G. Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett 2008;2:67-75
40. Nagar S, Raffa RB. Looking beyond the administered drug: Metabolites of opioid analgesics. J Fam Pract 2008;57:S1-8
41. Holmquist GL. Opioid metabolism and effects of cytrochrome P450. Pain Med 2009;10:S20-9
42. Coller JK, Christrup LL, Somogyi AA. Role of active metabolites in the use of opioids. Eur J Clin Pharmacol 2009;65:121-39
43. Lange B, Kuperwasser B, Okamoto A, et al. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther 2010;27:381-99
44. Jarlbaek L, Andersen M, Hallas J, et al. Use of opioids in a Danish population-based cohort of cancer patients. J Pain Symptom Manage 2005;29:336-43
45. Aulbert E, Nauck F, Radbruch L. editors. Lehrbuch der Palliativmedizin. Schattauer Verlag; Stuttgart, Germany: 2006
46. Vissers KC, Besse K, Hans G, et al. Opioid rotation in the management of chronic pain: Where is the evidence? Pain Pract 2010;10:85-93
47. ULTRAM-ER (tramadol HCl) Extended Release Tablets [package insert]. PriCara-Unit of Ortho-McNeil, Inc., Raritan, NJ:2007
48. Nucynta-ER (tapentadol) extended-release oral tablets C-II [package insert]. Janssen Pharmaceuticals, Inc.; Raritan, NJ: 2011
49. Cossmann M, Kohnen C. General tolerability and adverse event profile of tramadol hydrochloride. Rev Contemp Pharmacother 1995;6:513-31
50. Bamigbade TA, Langford RM. the clinical use of tramadol hydrochloride. Pain Rev 1998;5:155-82
51. Barkin RL. Extended-release tramadol (ULTRAM ER): A pharmacotherapeutic, pharmacokinetic, and pharmacodynamic focus on effectiveness and safety in patients with chronic/persistent pain. Am J Ther 2008;15:157-66
52. Riemsma R, Forbes C, Harker J, et al. Systematic review of tapentadol in chronic severe pain. Curr Med Res Opin 2011;27:1907-30
53. Hoy SM. Tapentadol extended release: In adults with chronic pain. Drugs 2012;72:375-93
54. Daniels SE, Golf M. Clinical efficacy and safety of tapentadol immediate release in the postoperative setting. J Am Podiatr Med Assoc 2012;102:139-48
55. Merker M, Dinges G, Koch T, et al. Undesired side effects of tapentadol in comparison to oxycodone. A metaanalysis of randomized controlled comparative studies. Schmerz 2012;26:16-26
56. Dayer P, Desmeules J, Collart L. Pharmacology of tramadol. Drugs 1997;53(Suppl 2):18-24
57. Cicero TJ, Inciardi JA, Adams EH, et al. Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: Results of an abuse monitoring system, 1994-2004. Pharmacoepidemiol Drug Saf 2005;14:851-9
58. Adams EH, Breiner S, Cicero TJ, et al. A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain. J Pain Symptom Manage 2006;31:465-76
59. Inciardi JA, Cicero TJ, Munoz A, et al. the diversion of Ultram-, Ultracet-, and generic tramadol HCl. J Addict Dis 2006;25:53-8
60. Hartrick C, Van Hove I, Stegmann J-U, et al. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: A 10-day, phase III, randomized, double-blind, active-and placebo-controlled study. Clin Ther 2009;31:260-71
61. Daniels SE, Upmalis D, Okamoto A, et al. A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin 2009;25:765-76
62. Afilalo M, Etropolski MS, Kuperwasser B, et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: A randomized, double-blind, placebo-and active-controlled phase III study. Clin Drug Investig 2010;30:489-505
63. Kress HG. Tapentadol and its two mechanisms of action: Is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain 2010;14:781-3
64. Fields HL, Martin JB. Pain: pathophysiology and management. In: Gaul C, Endres M, Erbguth F. editors. Harrison's neurology in clinical medicine; german edition. ABW Wissenschaftsverlag; Berlin, Germany: 2012;12:290-306
65. Pergolizzi J, Alon E, Baron R, et al. Tapentadol in the management of chronic low back pain: A novel approach to a complex condition? J Pain Res 2011;4:203-10
66. Pergolizzi J, Alegre C, Blake D, et al. Current considerations for the treatment of severe chronic pain: The potential for tapentadol. Pain Pract 2012
67. Suzuki R, Rygh LJ, Dickenson AH. Bad news from the brain: Descending 5-HT pathways that control spinal pain processing. Trends Pharmacol Sci 2004;25:613-17
68. Bannister K, Bee LA, Dickenson AH. Preclinical and early clinical investigations related to monoaminergic pain modulation. Neurotherapeutics 2009;6:703-12
69. Raffa RB, Friderichs E, Reimann W, et al. Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J Pharmacol Exp Ther 1993;267:331-40